<code id='DD2568F8F7'></code><style id='DD2568F8F7'></style>
      • <acronym id='DD2568F8F7'></acronym>
      <center id='DD2568F8F7'><center id='DD2568F8F7'><tfoot id='DD2568F8F7'></tfoot></center><abbr id='DD2568F8F7'><dir id='DD2568F8F7'><tfoot id='DD2568F8F7'></tfoot><noframes id='DD2568F8F7'>
      • <optgroup id='DD2568F8F7'><strike id='DD2568F8F7'><sup id='DD2568F8F7'></sup></strike><code id='DD2568F8F7'></code></optgroup>
        5. <b id='DD2568F8F7'><label id='DD2568F8F7'><select id='DD2568F8F7'><dt id='DD2568F8F7'><span id='DD2568F8F7'></span></dt></select></label></b><u id='DD2568F8F7'></u>
          <i id='DD2568F8F7'><strike id='DD2568F8F7'><tt id='DD2568F8F7'><pre id='DD2568F8F7'></pre></tt></strike></i>
           


   

   

   
   
   
   
   
   
   
   
   
   
   
   
   

   
   
   
   
   
   
   
  
           
  
           
  
           
   
           
    
           
     
           
      
           
       
      
           
      
           
       
           
        
           
         
           
           
          
           
         
           
         
           
           
          
           
         
           
          
        
           
       
           
       
           
        
           
        
           
        
           
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
       
           
       
           
        
           
        
          
          00:00 
        
           
       
           
       
           
      
           
      
           
        
        
        
       
           
        00:00 
         
        00:00 
        LIVE 
       
           
        
       
           
        
           
        
           
        
           
        
           
       
           
       
           
       
           
        
        
        
        
        
        
        
        
        
      
           
       
    
    
      
           
       
           
      
           
     
           
     
           
       
     
           
     
           
      
           
      
           
      
           
      
           
       
           
      
           
      
           
      
           
       
           
       
          
         buffering 
       
           
      
           
      
           
       
           
        
           
        
          
          Replay 
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
        
           
        
           
        
           
       
           
      
           
      
           
      
           
      
           
      
           
       
           
      
           
     
           
     
           
      
           
     
           
     
           
      
           
       
           
        
           
       
           
       
           
        
          
          LIVE 
        
           
        00:00 
         /  
        00:00 
       
           
       
           
        
           
        
           
        
           
         
           
         
           
         
           
         
           
         
           
         
           
        
           
        
           
        
           
       
           
       
           
        
           
        
          
          LIVE 
        
           
       
           
       
           
        
           
        
          
          CC 
        
           
       
           
       
           
        
           
       
           
       
           
       
           
        
           
        
           
         
           
        
           
       
           
       
           
        
           
       
           
      
           
      
           
       
           
        
           
        
           
         
           
         
           
         
           
          
           
          
           
          
           
         
           
        
           
       
           
      
           
      
           
       
           
     
       
           
    
       
           
       
    
  
       
           
   
       
           
       
       
           
      
           
      
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       Opacity : 
        
      
           
     
           
     
           
     
           
      
           
  
     
           
    
           
    
           
    
           
     
          
       Share: 
     
           
      
     
           
      
      Copy 
     
           
      
    
           
    
          
      Close 
      
    
           
    
           
      
    
           
    
           
   
           
  
           
  
           
    
    
    
   
           
   
           
 
    
   
           
   
           
   
           
    
           
     
           
      
           
       
           
        
           
          
          
         
          
          knowledge 

          
          
            
          
          

           
           
        
           
       
           
      
           
     
           
    
           
    
           
     
           
      
           
      
           

                       
          hotspot  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      -
 
browse：31645
                                  
                                    
          
                                    
            
          
 
          Boxes of Ozempic photo illustration. -- health coverage from STAT
          Mario Tama/Getty Images
          LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.
          Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.
          advertisement
          The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy. 
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
           
 
 
          

                              
          
                                 Previous article：

                                
                                          Supreme Court strikes down use of affirmative action
                                
                            
          Next article：  
                                      
                                          Medicare drug price negotiation legal challenge met with skepticism
                                                                    
          

      
           
      
           
        
           
                                               
        
           Wikipedia 
           
                   
      
           
  
  
          
    
          
        
          
            
          
                                                     
                
          leisure time
          
                            
          
        
          
        
    
          

          

    

      
           
     
           


   
    
           
   
           
  
 

  
           
    
           
           
           
            
            Back To Top 
           
           
           
           

            
           
                                                                    
                 
          knowledge
           
                                      
            
           
          
           
                                                          
             
          leisure time
           
                             
            
           
            
           

                                                         
             
          entertainment
           
               
              
            
           
            
           
                                                         
             
          hotspot
           
                             
      
           
 
     
           
     
           
      
          
              AlexHogan/STATWhenIinterviewedRonaldReaganabouthishealthin1980,hewas69andpoisedtobecometheoldestpers
             
           
      
          
        © 2013-2023.Company name All rights reserved.Site Map 
         WSS-More Templates  
             Guangdong ICP82675name